224 related articles for article (PubMed ID: 16842156)
1. Discovery and development of pyrazole-scaffold Hsp90 inhibitors.
McDonald E; Jones K; Brough PA; Drysdale MJ; Workman P
Curr Top Med Chem; 2006; 6(11):1193-203. PubMed ID: 16842156
[TBL] [Abstract][Full Text] [Related]
2. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.
Sharp SY; Boxall K; Rowlands M; Prodromou C; Roe SM; Maloney A; Powers M; Clarke PA; Box G; Sanderson S; Patterson L; Matthews TP; Cheung KM; Ball K; Hayes A; Raynaud F; Marais R; Pearl L; Eccles S; Aherne W; McDonald E; Workman P
Cancer Res; 2007 Mar; 67(5):2206-16. PubMed ID: 17332351
[TBL] [Abstract][Full Text] [Related]
3. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer.
McDonald E; Workman P; Jones K
Curr Top Med Chem; 2006; 6(11):1091-107. PubMed ID: 16842148
[TBL] [Abstract][Full Text] [Related]
5. Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors.
Kadasi S; Costa TEMM; Arukala N; Toshakani M; Duggineti C; Thota S; Dutta Gupta S; Raj S; Penido C; Henriques MG; Raghavendra NM
Med Chem; 2018; 14(1):44-52. PubMed ID: 28641528
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of hsp90 inhibitors as anti-cancer drugs.
Xiao L; Lu X; Ruden DM
Mini Rev Med Chem; 2006 Oct; 6(10):1137-43. PubMed ID: 17073714
[TBL] [Abstract][Full Text] [Related]
7. 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone.
Brough PA; Barril X; Beswick M; Dymock BW; Drysdale MJ; Wright L; Grant K; Massey A; Surgenor A; Workman P
Bioorg Med Chem Lett; 2005 Dec; 15(23):5197-201. PubMed ID: 16213716
[TBL] [Abstract][Full Text] [Related]
8. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
Hadden MK; Lubbers DJ; Blagg BS
Curr Top Med Chem; 2006; 6(11):1173-82. PubMed ID: 16842154
[TBL] [Abstract][Full Text] [Related]
9. 4-Amino derivatives of the Hsp90 inhibitor CCT018159.
Barril X; Beswick MC; Collier A; Drysdale MJ; Dymock BW; Fink A; Grant K; Howes R; Jordan AM; Massey A; Surgenor A; Wayne J; Workman P; Wright L
Bioorg Med Chem Lett; 2006 May; 16(9):2543-8. PubMed ID: 16480864
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the HSP90 molecular chaperone: current status.
Sharp S; Workman P
Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
[TBL] [Abstract][Full Text] [Related]
11. Discovery of N-pyridoyl-Δ
Kadasi S; Yerroju R; Gaddam S; Pullanagiri N; Chary M; Pingili D; Raj S; Raghavendra NM
Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900192. PubMed ID: 31808979
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues.
Sharp SY; Prodromou C; Boxall K; Powers MV; Holmes JL; Box G; Matthews TP; Cheung KM; Kalusa A; James K; Hayes A; Hardcastle A; Dymock B; Brough PA; Barril X; Cansfield JE; Wright L; Surgenor A; Foloppe N; Hubbard RE; Aherne W; Pearl L; Jones K; McDonald E; Raynaud F; Eccles S; Drysdale M; Workman P
Mol Cancer Ther; 2007 Apr; 6(4):1198-211. PubMed ID: 17431102
[TBL] [Abstract][Full Text] [Related]
13. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
Franke J; Eichner S; Zeilinger C; Kirschning A
Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.
Uno T; Kawai Y; Yamashita S; Oshiumi H; Yoshimura C; Mizutani T; Suzuki T; Chong KT; Shigeno K; Ohkubo M; Kodama Y; Muraoka H; Funabashi K; Takahashi K; Ohkubo S; Kitade M
J Med Chem; 2019 Jan; 62(2):531-551. PubMed ID: 30525599
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
Soga S; Akinaga S; Shiotsu Y
Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
[TBL] [Abstract][Full Text] [Related]
17. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
18. Radester, a novel inhibitor of the Hsp90 protein folding machinery.
Shen G; Blagg BS
Org Lett; 2005 May; 7(11):2157-60. PubMed ID: 15901158
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
